Sugammadex Injection
Product Images NDC 0641-6270

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Sugammadex (NDC 0641-6270). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hikma Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Sugammadex Injection Pfs 1)

An instructional diagram of a 2 mL single dose syringe labeled with 'Hikma'. The syringe includes a removable syringe tip cap, an external collar labeled 'Do Not Remove', and a plunger rod. Measurement markings for 1 mL and 2 mL volumes are visible on the syringe barrel.*

FDA Label Image

Figure 2 (Sugammadex Injection Pfs 2)

An instructional illustration showing two hands connecting or securing a medical device component, possibly involving twisting or screwing motion, indicated by a curved arrow. The image appears to guide assembly or attachment related to injection or intravenous use.*

FDA Label Image

Sugammadex Sodium Structural Formula (Sugammadex Injection Pfs 3)

Chemical structure diagram of Sugammadex, illustrating its molecular arrangement with detailed rings and linkage bonds, including sodium carboxylate groups.*

FDA Label Image

Oh-derivative Sugammadex Structural Formula (Sugammadex Injection Pfs 4)

Chemical structure of Sugammadex, depicting the detailed arrangement of atoms and bonds in the molecule used as an intravenous injection by Hikma Pharmaceuticals USA Inc.*

FDA Label Image

Section 14.1 (Figure 1)

This is a cumulative recovery rate chart comparing the recovery times of sugammadex 2 mg/kg versus neostigmine 0.05 mg/kg after rocuronium administration. The x-axis shows time to recovery in minutes up to 120, and the y-axis shows the cumulative recovery rate from 0 to 1. Sugammadex shows a much faster recovery median time (1.4 minutes) compared to neostigmine (21.5 minutes), as indicated by the steep recovery curve and median recovery times in the inset.*

FDA Label Image

Section 14.1 (Figure 2)

A cumulative recovery rate graph comparing sugammadex 2 mg/kg and neostigmine 0.05 mg/kg, showing recovery over time in minutes up to 120. The graph includes median recovery times with quartiles: sugammadex at 2.1 minutes and neostigmine at 29.0 minutes, indicating recovery speed differences.*

FDA Label Image

Sugammadex Pfs Lbl (Sugammadex Injection Pfs 7)

Label for Sugammadex Injection, 200 mg per 2 mL (100 mg/mL), intravenous injection in a 2 mL single-dose prefilled syringe. The label specifies storage at 25°C, protection from light, and discarding unused portions. Manufactured by Hikma Pharmaceuticals USA Inc. The label includes NDC 0641-6270-01 and a barcode.*

FDA Label Image

Sugammadex Pfs Ctn (Sugammadex Injection Pfs 8)

Carton label for Sugammadex Injection 200 mg per 2 mL (100 mg/mL) by Hikma Pharmaceuticals USA Inc. The label indicates the product is for intravenous use only, packaged as 10 single-dose prefilled syringes. It includes dosage and storage instructions, barcode, and manufacturer information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.